查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1386335

B 細胞淋巴瘤治療市場報告：2030 年趨勢、預測與競爭分析

B-Cell Lymphoma Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

B 細胞淋巴瘤治療的趨勢和預測

預計到 2030 年，全球 B 細胞淋巴瘤治療市場將達到 102.8 億美元，2024 年至 2030 年複合年成長率為 7.8%。該市場的主要促進因素是 B 細胞淋巴瘤盛行率的增加和治療方案的不斷進步。全球B細胞淋巴瘤治療市場前景廣闊，醫院、專科診所及家庭醫療保健市場蘊含商機。

B 細胞淋巴瘤治療市場洞察

Lucintel 預測，由於 B 細胞淋巴瘤病例數的增加和盛行率的增加，在預測期內，瀰漫性大 B 細胞淋巴瘤仍將是最大的部分。

醫院可能仍然是該市場中最大的部分，因為它們提供必要的設備和專業知識來進行廣泛的 B 細胞淋巴瘤治療。

由於北美擁有發達的醫療保健系統，可以獲得最新的 B 細胞淋巴瘤治療方法，預計在預測期內仍將是最大的市場。

市場規模/估計：以金額（B 美元）估計 B 細胞淋巴瘤治療的市場規模。

趨勢和預測分析：各個區隔市場和地區的市場趨勢（2018-2023）和預測（2024-2030）。

區隔分析：依類型、最終用途、配銷通路和地區金額（十億美元）估計 B 細胞淋巴瘤治療市場規模。

區域分析：北美、歐洲、亞太地區和世界其他地區 B 細胞淋巴瘤治療市場的區域區隔。

成長機會：依類型、最終用途、配銷通路和地區分析 B 細胞淋巴瘤治療市場的成長機會。

策略分析： B細胞淋巴瘤治療市場併購、新產品開發、競爭形勢等。

基於波特五力模型的產業競爭實力分析。

本報告回答了 11 個關鍵問題：

  • Q.1. 區隔市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個區隔市場將以更快的速度成長？為什麼？
  • Q.3.哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要課題和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去五年發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章執行摘要

第2章全球B細胞淋巴瘤治療市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與課題

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球B細胞淋巴瘤治療市場趨勢（2018-2023）與預測（2024-2030）
  • 依類型分類的全球 B 細胞淋巴瘤治療市場
    • 瀰漫性大B細胞淋巴瘤
    • 淋巴漿細胞淋巴瘤
    • 毛細胞白血病
    • 原發性中樞神經系統淋巴瘤
    • 原發性眼內淋巴瘤
    • 其他
  • 依最終用途分類的全球 B 細胞淋巴瘤治療市場
    • 醫院
    • 專科診所
    • 家庭保健
    • 其他
  • 依配銷通路的全球 B 細胞淋巴瘤治療市場
    • 直接競標
    • 醫院藥房
    • 零售藥房
    • 線上藥房
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球B細胞淋巴瘤治療市場（依地區）
  • 北美B細胞淋巴瘤治療市場
  • 歐洲B細胞淋巴瘤治療市場
  • 亞太B細胞淋巴瘤治療市場
  • 其他地區B細胞淋巴瘤治療市場

第5章競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 依類型分類的全球 B 細胞淋巴瘤治療市場成長機會
    • 全球 B 細胞淋巴瘤治療市場成長機會（依最終用途）
    • 全球 B 細胞淋巴瘤治療市場成長機會（依配銷通路）
    • 全球 B 細胞淋巴瘤治療市場依地區成長機會
  • 全球B細胞淋巴瘤治療市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球 B 細胞淋巴瘤治療市場的產能
    • 全球B細胞淋巴瘤治療市場的合併、收購與合資企業
    • 認證和許可

第7章主要企業概況

  • Pfizer
  • Celgene Corporation
  • Eli Lilly
  • Novartis
  • Genentech
  • AstraZeneca
  • F. Hoffmann-La Roche
  • Eisai
  • Amgen
  • Merck
簡介目錄

B-Cell Lymphoma Treatment Trends and Forecast

The future of the global B-cell lymphoma treatment market looks promising with opportunities in the hospital, specialty clinic, and home healthcare markets. The global B-cell lymphoma treatment market is expected to reach an estimated $10.28 billion by 2030 with a CAGR of 7.8% from 2024 to 2030. The major drivers for this market are growing incidence of B-cell lymphomas and on-going advancements in the treatment options.

A more than 150-page report is developed to help in your business decisions.

B-Cell Lymphoma Treatment by Segment

The study includes a forecast for the global B-cell lymphoma treatment by type, end use, distribution channel, and region.

B-Cell Lymphoma Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Diffuse Large B-Cell Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Hairy Cell Leukemia
  • Primary Central Nervous System Lymphoma
  • Primary Intraocular Lymphoma
  • Others

B-Cell Lymphoma Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Others

B-Cell Lymphoma Treatment Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Direct Tender
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

B-Cell Lymphoma Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of B-Cell Lymphoma Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies B-cell lymphoma treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the B-cell lymphoma treatment companies profiled in this report include-

  • Pfizer
  • Celgene Corporation
  • Eli Lilly
  • Novartis
  • Genentech
  • Astrazeneca
  • F. Hoffmann-La Roche
  • Eisai
  • Amgen
  • Merck

B-Cell Lymphoma Treatment Market Insights

Lucintel forecasts that diffuse large B-cell lymphoma will remain the largest segment over the forecast period due to increase number of cases and growing prevalence of B-cell lymphomas.

Within this market, hospital will remain the largest segment as it provides necessary equipment and expertise to perform a wide range of B-cell lymphoma treatments.

North America will remain the largest segment over the forecast period due to presence of well-developed healthcare system with access to the latest B-cell lymphoma treatments in the region.

Features of the Global B-Cell Lymphoma Treatment Market

Market Size Estimates: B-cell lymphoma treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: B-cell lymphoma treatment market size by type, end use, distribution channel, and region in terms of value ($B).

Regional Analysis: B-cell lymphoma treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, end uses, distribution channels, and regions for the B-cell lymphoma treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the B-cell lymphoma treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the B-cell lymphoma treatment market size?

Answer: The global B-cell lymphoma treatment market is expected to reach an estimated $10.28 billion by 2030.

Q.2 What is the growth forecast for B-cell lymphoma treatment market?

Answer: The global B-cell lymphoma treatment market is expected to grow with a CAGR of 7.8% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the B-cell lymphoma treatment market?

Answer: The major drivers for this market are growing incidence of B-cell lymphomas and on-going advancements in the treatment options.

Q4. What are the major segments for B-cell lymphoma treatment market?

Answer: The future of the global B-cell lymphoma treatment market looks promising with opportunities in the hospital, specialty clinic, and home healthcare markets.

Q5. Who are the key B-cell lymphoma treatment market companies?

Answer: Some of the key B-cell lymphoma treatment companies are as follows:

  • Pfizer
  • Celgene Corporation
  • Eli Lilly
  • Novartis
  • Genentech
  • Astrazeneca
  • F. Hoffmann-La Roche
  • Eisai
  • Amgen
  • Merck

Q6. Which B-cell lymphoma treatment market segment will be the largest in future?

Answer: Lucintel forecasts that diffuse large B-cell lymphoma is expected to witness highest growth over the forecast period due to fast-growing lymphoma that can affect people of all ages, but it is most common in older adults.Lucintel forecasts that diffuse large B-cell lymphoma will remain the largest segment over the forecast period due to increase number of cases and growing prevalence of B-cell lymphomas.

Q7. In B-cell lymphoma treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to presence of well-developed healthcare system with access to the latest B-cell lymphoma treatments in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the B-cell lymphoma treatment market by type (diffuse large B-cell lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, primary central nervous system lymphoma, primary intraocular lymphoma, and others), end use (hospitals, specialty clinics, home healthcare, and others), distribution channel (direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global B-Cell Lymphoma Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global B-Cell Lymphoma Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global B-Cell Lymphoma Treatment Market by Type
    • 3.3.1: Diffuse Large B-Cell Lymphoma
    • 3.3.2: Lymphoplasmacytic Lymphoma
    • 3.3.3: Hairy Cell Leukemia
    • 3.3.4: Primary Central Nervous System Lymphoma
    • 3.3.5: Primary Intraocular Lymphoma
    • 3.3.6: Others
  • 3.4: Global B-Cell Lymphoma Treatment Market by End Use
    • 3.4.1: Hospitals
    • 3.4.2: Specialty Clinics
    • 3.4.3: Home Healthcare
    • 3.4.4: Others
  • 3.5: Global B-Cell Lymphoma Treatment Market by Distribution Channel
    • 3.5.1: Direct Tender
    • 3.5.2: Hospital Pharmacy
    • 3.5.3: Retail Pharmacy
    • 3.5.4: Online Pharmacy
    • 3.5.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global B-Cell Lymphoma Treatment Market by Region
  • 4.2: North American B-Cell Lymphoma Treatment Market
    • 4.2.2: North American B-Cell Lymphoma Treatment Market by End Use: Hospitals, Specialty Clinics, Home Healthcare, and Others
  • 4.3: European B-Cell Lymphoma Treatment Market
    • 4.3.1: European B-Cell Lymphoma Treatment Market by Type: Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma, and Others
    • 4.3.2: European B-Cell Lymphoma Treatment Market by End Use: Hospitals, Specialty Clinics, Home Healthcare, and Others
  • 4.4: APAC B-Cell Lymphoma Treatment Market
    • 4.4.1: APAC B-Cell Lymphoma Treatment Market by Type: Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma, and Others
    • 4.4.2: APAC B-Cell Lymphoma Treatment Market by End Use: Hospitals, Specialty Clinics, Home Healthcare, and Others
  • 4.5: ROW B-Cell Lymphoma Treatment Market
    • 4.5.1: ROW B-Cell Lymphoma Treatment Market by Type: Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma, and Others
    • 4.5.2: ROW B-Cell Lymphoma Treatment Market by End Use: Hospitals, Specialty Clinics, Home Healthcare, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global B-Cell Lymphoma Treatment Market by Type
    • 6.1.2: Growth Opportunities for the Global B-Cell Lymphoma Treatment Market by End Use
    • 6.1.3: Growth Opportunities for the Global B-Cell Lymphoma Treatment Market by Distribution Channel
    • 6.1.4: Growth Opportunities for the Global B-Cell Lymphoma Treatment Market by Region
  • 6.2: Emerging Trends in the Global B-Cell Lymphoma Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global B-Cell Lymphoma Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global B-Cell Lymphoma Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Pfizer
  • 7.2: Celgene Corporation
  • 7.3: Eli Lilly
  • 7.4: Novartis
  • 7.5: Genentech
  • 7.6: AstraZeneca
  • 7.7: F. Hoffmann-La Roche
  • 7.8: Eisai
  • 7.9: Amgen
  • 7.10: Merck